AlbaniaTuberculosis profile
Population  2015 2.9 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.01 (<0.01–0.015) 0.35 (0.22–0.51)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.05 (0–0.17)
Incidence  (includes HIV+TB) 0.55 (0.46–0.63) 19 (16–22)
Incidence (HIV+TB only) <0.01 (<0.01–0.01) 0.27 (0.21–0.34)
Incidence (MDR/RR-TB)** 0.015 (<0.01–0.027) 0.52 (0.1–0.93)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.018 (<0.01–0.03) 0.15 (0.091–0.22) 0.17 (0.097–0.25)
Males 0.032 (0.021–0.043) 0.34 (0.27–0.42) 0.37 (0.29–0.46)
Total 0.05 (0.036–0.064) 0.5 (0.45–0.54) 0.55 (0.46–0.63)
TB case notifications, 2015  
Total cases notified 415
Total new and relapse 415
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 44%
          - % pulmonary 72%
          - % bacteriologically confirmed among pulmonary 71%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 76% (65–89)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.02 (0.01–0.03)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 6 3%
          - on antiretroviral therapy 6 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  8
(1–15)
Estimated % of TB cases with MDR/RR-TB 2.3% (0.64–5.8) 6.7% (0.17–32)  
% notified tested for rifampicin resistance 2% 29% 13
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 4, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 3, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 88% 406
Previously treated cases, excluding relapse, registered in 2014   0
HIV-positive TB cases, all types, registered in 2014 100% 2
MDR/RR-TB cases started on second-line treatment in 2013    
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
8% (5.9–12)
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-06 Data: www.who.int/tb/data